{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.41","value":"136"},{"groupId":"OG001","lowerLimit":"12.82","value":"65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"434"},{"groupId":"OG001","value":"439"}],"units":"Participants"}],"description":"Number of participants who discontinued treatment due to toxicity are reported in this outcome measure.","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"},{"description":"Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.","id":"OG001","title":"Sunitinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)","title":"Number of Participants Who Discontinued Treatment Due to Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}